

1 UNITED STATES OF AMERICA
2 NUCLEAR REGULATORY COMMISSION

3 ***

4 WORKSHOP TO DEVELOP A STANDARD REVIEW PLAN
5
6
7

8 USNRC

9 Two White Flint North

10 Auditorium

11 11545 Rockville Pike,

12 Rockville, Maryland
13

14 Friday, February 18, 2000
15

16 The workshop commenced, pursuant to notice, at 8:48 a.m.
17
18
19
20
21
22
23
24
25

ANN
RIL
EY
&
ASS
OCI
ATE

P R O C E E D I N G S

[8:48 a.m.]

1
2
3 ORLANDO: This is day two of our workshop on standard review
4 plan for decommissioning. Again, for the record, I'm Nick Orlando. I'm
5 the project manager in the Division of Waste Management, who has the
6 lead for putting together the SRP. As I said yesterday, what we were
7 planning on doing today is open the floor up again to discussion of SRP
8 module 15 and 16 if anybody has anything else they'd like to say about
9 that. The agenda also shows some time at 9:30 to discuss any issues
10 that anybody wants to bring up.

11 If there are no additional comments on SRP module 15 or 16,
12 we'll move on to that, and if there is no interest in discussing any
13 additional items, then, we will move on to the presentations that Bobby
14 and Mark have. I believe you guys put some -- that's your slides out on
15 the front, right? Okay; thank you very much.

16 Does anybody have anything else they would like to say about
17 module 15 or 16?

18 [No response.]

19 ORLANDO: Make it easy on me. Is anybody here today that
20 wasn't here yesterday?

21 [Show of hands.]

22 ORLANDO: Okay; do you have anything you'd like to say about
23 module 15 or 16 of the standard review plan? I'm sorry; the meeting is
24 being transcribed, so if you could come up and speak into the
25 microphone, please.

PRICE: My name is Joe Price, and I work for SAIC. My role
in life is to do dose analysis, usually for site-specific situations,
and so, that's where I'm most interested in getting guidance, which I
guess in the versions of the documents that I had hadn't been carried
forward, so I guess I would be interested in knowing where the NRC is

ADN
RIL
EY
&
ASS
OCI
ATE

1 going with guidance on site-specific analyses.

2 ORLANDO: Okay; on the Web right now, module 5, which is the
3 dose modeling module, it's divided into six or five sections, 5-01, 2,
4 3, 4. 01 and 2 are on the Web now. I hope to have 3 and 4 out
5 relatively soon. One of the things you'll notice, even looking at
6 module 1 and 2 is that it refers to a technical basis document. The
7 staff is still developing that, and we hope to have that out on the Web
8 for review in April. So that's where we are with the dose modeling.

9 In addition, since you weren't here yesterday, we hope to
10 have a set of probabilistic distributions for RESRAD and D&D Version 2,
11 which will be a probabilistic version, correct, available in the summer
12 of this year. So that's about where we are with dose modeling, okay?

13 PRICE: Thank you.

14 ORLANDO: In addition, you may or may not be aware; we had
15 two Federal Register notices that have tables of screening values, one
16 for surfaces, equipment, building walls and things like that, and the
17 other for surface soil.

18 Okay; anybody? Dave Culberson.

19 CULBERSON: Dave Culberson; I have a general comment. Do
20 you want to take that now or wait until the next -- SRP as a whole?

21 ORLANDO: No, I think now is fine.

22 CULBERSON: Okay; I was talking with a couple of our members
23 this morning, and we had a suggestion that since DG-4006 is now going to
24 be absorbed into the SRP, there are some sections, particularly at the
25 beginning of DG-4006 and at the beginning, lead-in paragraphs to the
various sections that have some very useful overarching information
about the decommissioning process as a whole; NRC's process on -- the
approach; some of the regulatory positions and good discussion that I
think, since the SRP will be a single document, it will be useful to
have in there for both the licensees as well as the NRC reviewers, and

ADN
RIL
EY
&
ASS
OCI
ATE

1 our suggestion would be that those parts of the 4006 maybe be captured
2 as well as maybe even an individual module at the beginning of the SRP
3 to provide this broad-based, overarching information about the
4 decommissioning process; the approach, some of the philosophy, how you
5 go about modeling, how you go about deriving in a more philosophical
6 sense than the specifics we'll get into in individual sections.

7 And one thing that we could offer if you had any interest in
8 that is I was talking to John Konig this morning. We'd be willing to
9 get a copy on the electronic version of 4006 if we could and take a
10 crack on that to give you a straw man to go from just to kind of reflect
11 our -- what we believe is the useful information out here and just pass
12 that along to you as a starting point, if we could have a couple of
13 weeks to work on that. And then, Field Cycle Forum has a meeting coming
14 up next month that we would anticipate discussing a combination of 4006
15 and the SRP. We would like to generate some comments from that meeting
16 that we get to you later. We would also, you know, any additional
17 comments the group may have, we'd like to submit as well, but we would
18 volunteer to do that if that would be of interest.

19 ORLANDO: You could do that. I can't guarantee that, you
20 know, what eventually ends up in the standard review plan will look
21 anything like that or if we will even go that route, but, I mean, you
22 know, if you feel that there is some valuable information in the front
23 of the DG that you think gives a good overview, sure.

24 You said that you thought you would try to get that to us
25 within a couple weeks. How far out are we looking?

CULBERSON: John Konig and I were talking about this, and we
were going to try to work on it together. End of February?

ORLANDO: That's fine. It could even go a little bit into
March, because I won't be back until the first week of March anyway.

CULBERSON: We have a meeting scheduled the second week in

ADN
RIL
EY
&
ASS
OCI
ATE

1 March, and we could expect to generate some additional comments at that
2 that we will formalize and have for you.

3 ORLANDO: The additional comments on the DG?

4 CULBERSON: No, the 4000, the SRP.

5 ORLANDO: The SRP? Okay.

6 CULBERSON: The standard review plan.

7 ORLANDO: Please expedite those because --

8 CULBERSON: We will.

9 ORLANDO: -- we do have to start working on the --

10 CULBERSON: We will try to have those in to you by the end
11 of March.

12 ORLANDO: Okay; we did say yesterday we could, you know,
13 take them through mid-March if -- okay, sure.

14 Please identify yourself.

15 MORTON: Henry Morton.

16 There are a couple of areas of subject matter in DG-4006,
17 for example, the methodology for ALARA analysis and some provisions from
18 NUREG 1505, some survey methodology that was covered in 1505 that was
19 not in the MARSSIM that's in DG-4006.

20 At this point, how do you anticipate that you would
21 incorporate that kind of material into the standard review plan?

22 ORLANDO: I'm still trying to think how I'm going to bring
23 the DG into the standard review plan, so I'm really not ready to get
24 into the specifics of that. Originally, what we had planned to do was
25 leave the DG as an appendix, but it may be better to keep certain
sections as an appendix and maybe just bring the words up into the SRP.
I'm still trying to figure out the best way to do that so -- it depends
a lot on the impact of the comments that we got on the DG.

[Pause.]

ORLANDO: Anybody else have any comments or questions on

ADN
RIL
EY
&
ASS
OCI
ATE

1 anything?

2 [No response.]

3 ORLANDO: Anybody have any comments or questions about any
4 other broader issues? Any statements they would like to make or
5 anything they would like to say about something other than the standard
6 review plan?

7 [No response.]

8 ORLANDO: Okay; Mark or Bobby, whichever one wants to go
9 first.

10 EID: We have two speakers: Mark and Dick Cordell. Dick
11 Cordell will be coming soon and bringing his slides. I'll be here just
12 to answer comments and questions if you have any.

13 THAGGARD: Okay; can everybody hear me?

14 If you look at the original -- yes, we're getting a little
15 feedback here -- if you look at the original agenda, you see that we
16 were going to talk about the treatment of uncertainty first, and Dick
17 Cordell is going to give that presentation, and he's still making copies
18 of his slides, so his presentation will follow mine.

19 I'm going to talk about some criteria that we've been
20 developing on how to establish conceptual models. We're still getting
21 some feedback here. It must be --

22 [Pause.]

23 THAGGARD: Hopefully, this will work; yes, okay.

24 Okay; anyway, good morning, everybody. My name is Mark
25 Thaggard. I think most of you know me. I'm a senior analyst here in
the Division of Waste Management. As we've already talked about
yesterday and a little bit this morning, we are in the process of
developing a technical basis document, which is going to have a lot of
the information on the dose modeling, and we thought that we would cover
a couple of components of that technical basis document this morning, in

ADN
RIL
EY
&
ASS
OCI
ATE

1 particular, how we are going to be dealing with the treatment of
2 uncertainty. That's going to be covered in the technical basis
3 document. And also, this issue about establishing conceptual models.
4 That's going to be covered in the technical basis document. There are
5 some other important issues that are going to be covered in there, like
6 how to change land use scenarios; how to change parameters; things like
7 that that are going to be covered in a lot more detail in the technology
8 basis document than what you're going to see in the standard review
9 plan, when it's -- the sections of the standard review plan when they
10 are put up on the Website.

11 So we thought we would cover a couple of the components of
12 the technical basis document this morning. We are going to have another
13 workshop in June to cover the whole technical basis document.

14 What I want to talk about this morning is I want to talk
15 about three particular -- three specific -- I want to cover three
16 specific things. I want to first of all define what we're talking about
17 when we say conceptual models; talk a little bit about why we should be
18 interested in this area; then talk mostly about some of the issues that
19 relate -- some of the issues in terms of establishing conceptual models
20 that are covered in the technical basis document.

21 And then, I want to end with an example of why this is
22 important, and I'm going to use something out of the RESRAD as an
23 example. And I have to apologize at the beginning here that some of
24 this may seem kind of fundamental to some of you. If any of you have a
25 background in groundwater hydrology and things of that nature, you may
be very familiar with establishing a conceptual model, and this may seem
like somewhat basic to you, but I've reviewed a lot of dose analysis in
my time here at the NRC, and I think there seemed to be a fundamental
lack of understanding about establishing conceptual models and how
important that is in terms of the dose analysis. So, this is one of the

ADN
RIL
EY
&
ASS
OCI
ATE

1 reasons that we pulled it out and are talking about it specifically as a
2 special section in the technical basis document.

3 But this is my definition of what I mean by conceptual
4 model, and I will say that this is my definition. Other people may have
5 a slightly different definition, but the main thing we're talking about
6 is we're talking about some kind of qualitative description of what
7 we're trying to analyze, and usually, this involves developing some type
8 of illustration of what we're trying to analyze. And there are some
9 things that should be shown in that illustration. We should identify
10 the source of our contamination, where the contaminants are likely to go
11 and where they're going to wind up at the end. That's basically what we
12 are trying to demonstrate in this illustration.

13 It should also identify the assumptions that we're making.
14 Ultimately, what we're trying to do with developing a conceptual model
15 is we're trying to build something that we can develop mathematical
16 equations, and from those mathematical equations, we could carry out the
17 analysis. So before we develop the mathematical equations, we've got to
18 know what we're trying to analyze, and that's what the conceptual model
19 gives us.

20 Okay; I took this picture out of the RESRAD users' manual.
21 This is a good example, in my opinion, of a conceptual model. It shows
22 the source of contamination here; how the contaminants can migrate
23 through the environment; the ultimate receptor location, these
24 individuals here. So assuming that this was our site, and this was the
25 picture that we created of our site, how we are going to be analyzing
the site, then, we could -- once we've developed this picture here, we
could develop the mathematical equations to show how the contaminants
are going to move and what concentrations they're going to get, they're
& going to get; the concentrations that we're going to get at the place
OCI where the people can be exposed. That's what we're ultimately trying to
ATE

ADN
RIL
EY
&
ASS
OCI
ATE

1 get, and from that, we can do the dose analysis.

2 But before we can develop those mathematical equations,
3 we've obviously got to have a picture, and most times, we do have a
4 picture, at least in our mind, of what we're trying to analyze, but what
5 we're saying is you need to take it a little bit further than that and
6 actually put that mental picture on paper. And so that's what we've
7 done in this case here.

8 Now, some of you may be saying, well, why should we even be
9 concerned about this? After all, we're just going to run the RESRAD
10 code. Do we really need to be bothered with all this stuff about
11 conceptual models and all that kind of stuff? Well, first of all, even
12 if you're running the code that has a predefined conceptual model, like
13 the RESRAD code or the D&D code, those codes have their own conceptual
14 models. You need to know what assumptions you're making, what
15 assumptions are being made in that code and whether those assumptions
16 are applicable for your particular site.

17 And so, what we recommend in the technical basis document
18 is, first of all, that you should develop a conceptual model, and it
19 should be more than just a mental picture. You should actually develop
20 what you're trying to analyze. You should write it down, so that that
21 way, you can identify the assumptions that you're making, and then, you
22 can easily determine whether those assumptions are compatible with the
23 assumptions that are being made in the code that you are running.

24 Now, obviously, if you are not using a code like RESRAD, and
25 you are actually going through the process of developing your own
computer code, where you're developing your own mathematical equations
and things of that nature, obviously, you definitely need to have a
conceptual model, because you need to know what you are modeling. But
the main reason that we are interested in this issue about the
development of a conceptual model is because this could be one of the

ADN
RIL
EY
&
ASS
OCI
ATE

1 biggest sources of uncertainty in the analysis. In fact, the
2 uncertainty in establishing the conceptual model can be much bigger than
3 the uncertainty in any of the parameter values that you put into the
4 code, so you may spend a lot of effort gathering information about your
5 parameters, and then, you don't put that much effort into defining your
6 conceptual model.

7 Well, the conceptual model, the errors in that may
8 overwhelm, just completely mask any errors that you have in terms of the
9 parameter values that you put into the code, and unfortunately, the
10 uncertainty in our conceptual model is very difficult to quantify. And
11 so, this may be a source of uncertainty that you won't even know or you
12 won't have quantified, so, this is why we think this is important,
13 important enough to treat as a separate section in the technical basis
14 document.

15 Now, we will point out that one of the things that we're not
16 going to recommend in the technical basis document, we are not going to
17 advocate that people try to quantify the uncertainty in their models.
18 We recognize that this is a big source of uncertainty in the analysis,
19 but we're not going to advocate to people that they have to try to
20 quantify this. That's not something that we are advocating.

21 Now, if you were to -- most of you are familiar with NUREG
22 1549, where we've laid out the framework for doing the dose analysis.
23 I've just taken a piece of it here. Establishing the conceptual model
24 would be step three of that framework, so after you've collected your
25 data for your site, and you've established your scenarios, then, you
would establish your conceptual model if you are following a decision
framework.

ADN
RIL
EY
&
ASS
OCI
ATE
Okay; now -- I've got to back up here -- I've got a little
bit of problem with my computer here.

[Pause.]

1 THAGGARD: At any rate, we missed a page. I think most of
2 you have those handouts. Basically, that page I skipped over, I'm going
3 to be covering three main issues that we've attempted to address in the
4 technical basis document in terms of the conceptual model, and those
5 issues are what should be included in the conceptual model; how should
6 we address the multiple conceptual models; and how we should use
7 computer codes that have predefined conceptual models. Those are the
8 three issues that I'm going to cover.

9 And we talk about, to some extent, in the technical basis
10 document -- the first one is what should be included in the conceptual
11 model. Well, we started writing up this section of the technical basis
12 document; we realized that there are two primary areas that need to be
13 addressed in establishing your conceptual model. First has to deal with
14 the source term. The second has to deal with the environmental
15 transport. Issues and components of the analysis dealing with the
16 biosphere and the dosimetry, those are usually tied up with the land use
17 scenario, and so, those are treated in a separate part of the technical
18 basis document.

19 And so, in this part of the technical basis document dealing
20 with conceptual models, we primarily deal with establishing conceptual
21 models related to the source term and environmental transport. The
22 other aspects are dealt with primarily in the land use scenario part of
23 the document. These two areas here, the source term and environmental
24 transport, we expect to be areas where you're going to have the most
25 change from one site to the next.

 Okay; we look at the source term. I've listed here some of
the components of the source term that should be considered when you're
developing your conceptual model for the source term. In the technical
basis document, we go into a lot more detail talking about these issues.
Let me just point out a couple to talk about here. First of all, let's

ADN
RIL
EY
&
ASS
OCI
ATE

1 look at this component, the release mechanism. It's really important
2 when you're developing the conceptual model for your source term that
3 you think about how the assumptions that you're making about how the
4 radionuclides are going to be released.

5 I think I mentioned at a workshop a few months back when we
6 were talking about the issue about globalization about the fact that if
7 you've got radionuclides that are tied up in a concrete matrix, for
8 example, you probably want to look at modeling that through some type of
9 diffusion process. Well, before you can think about that, you need to
10 know what assumptions you're making about the release mechanism. Also,
11 you need to think about what assumptions you're going to make about the
12 containment failure. Some sites, there may be buried drums or something
13 like that where you -- obviously, you've got to make some assumptions
14 about how those drums fail, when they fail and things of that nature.

15 So, these are just some of the components that should be
16 covered in establishing the conceptual model for the source term area.
17 We look at the environmental transport. We're talking about primarily
18 transport through the air, groundwater and surface water. In the
19 technical basis document, we go into pretty good detail about aspects of
20 the air, groundwater and surface water; components of the conceptual
21 model -- I mean, components of those pathways that should be considered
22 in establishing your conceptual model.

23 Most of the sites that we deal with, we're going to have
24 very limited data, and this is why I said at the beginning that if you
25 have a hydrologic background, you're probably used to establishing
conceptual models, because you're used to dealing with limited data, and
anytime you have limited data, it may be possible that you can get more
than one interpretation of that data, and so, if you -- the issue
& arrives that if you've got more than one interpretation of the data,
ASS which interpretation should be used in the analysis.
OCI
ATE

1 And this is a much bigger problem than most of you may
2 realize, because, for example, if you've got data at your site, and you
3 come up with an interpretation of that data to establish your conceptual
4 model, I may look at that same data and come up with a completely
5 different interpretation, and, you know, we both could be correct, I
6 mean, in terms of the data. So, you get down to the question, well,
7 which conceptual model should we use? And sometimes, that can have a
8 big influence on the results, and I'm going to show an example of this a
9 little later when I go through the example using the RESRAD code, but
10 the main issue is that we could have multiple interpretations of the
11 same data, and they could be equally plausible based upon the review of
12 that data.

13 And what we're recommending in the technical basis document
14 is that if you've got more than -- if there's more than one conceptual
15 model at your site, based on the available data, you should use the most
16 conservative one to do the analysis, the most conservative one that's
17 consistent with the available data. Now, we're not advocating that you
18 automatically go out and start coming up with unrealistic conceptual
19 models, but if you can look at that data and come up with more than one
20 interpretation of that data, you should use the most conservative one to
21 do the analysis. That's what we're advocating, but it needs to be
22 consistent with the data, so we're not asking you to make up something
23 that's not consistent with the data.

24 Now, I saw a couple of frowns when I said that, but if you
25 think about this from a logical standpoint, if there's more than one
interpretation of that data, how can you not use the most conservative?
Because that means that there is not a plausible explanation of that
data that somebody can reasonably come up with, and so, unless you can
& convince me that that's not going to happen, then, I would say that you
need to use the more conservative one to establish whether you meet the

ADN
RIL
EY
&
ASS
OCI
ATE

1 dose criteria.

2 Now, again, the main thing we've got to look at here is that
3 we're saying it's consistent with the data. Obviously, if you use that
4 conservative conceptual model, and you don't pass, well, one of the
5 things that you may want to do is you may want to go out and get some
6 more data, because maybe some more data may be able to help you narrow
7 down which conceptual model is appropriate.

8 Now, one of the other issues that we talk about in the
9 technical basis document, and the reason that we specifically talk about
10 this for decommissioning is because I think a lot of people are going to
11 use codes off the -- you know, codes off the shelf, you know, like
12 RESRAD and D&D and things of that nature, you know. Now, one of the
13 issues that we wrestled with is how can we use codes that have
14 predefined conceptual models? Both D&D and RESRAD deal -- they have
15 their own inherent conceptual model, I mean, in terms of what they are
16 assuming the site looks like.

17 Well, first of all, the first suggestion we have is don't
18 use these codes with blinders on. This may seem kind of obvious, but
19 I've been at the agency for over 10 years, and believe me, I've seen a
20 lot of people use these codes with blinders on, and a lot of times,
21 people have in their mind what they are attempting to model, but that
22 doesn't -- it doesn't come anywhere close to the assumptions that are in
23 those codes, and so, that's why we advocate that you need to develop a
24 conceptual model at your site to make sure that that conceptual model
25 that you've developed for your particular site is consistent with what's
being assumed in the code.

Now, we're saying here that all of the assumptions in the
code don't have to match all of the assumptions in your conceptual
model. That's not what we're saying, because the key is that you want
to make sure that where there are differences, you document those

ADN
RIL
EY
&
ASS
OCI
ATE

1 differences; you know what the differences are and that those
2 differences are not going to lead to underestimation of the dose.
3 That's the key. We're not saying that, you know, all the assumptions
4 have to match up.

5 Okay; I want to go through a somewhat simpler illustration
6 to kind of point out why we are talking about this conceptual model
7 thing and why it's important. I think most of you are familiar with the
8 RESRAD code, the fact that there are two approaches in there for how you
9 model the groundwater, the contaminants reaching the groundwater. One
10 approach is what they call the mass balance approach. Let me explain
11 this figure here. This is a cross-section. Just assume that this is a
12 cross-section, and this little hole here in the middle is a well. We've
13 got a contaminated zone; an unsaturated zone; and this thing down here
14 at the bottom is our saturated zone.

15 This little triangle here is our contaminants. Now, what
16 the mass balance approach in the RESRAD assumes is, first of all, that
17 the well is in the center of the area of contamination. The other
18 assumption that it makes is that all of the contaminant that reaches the
19 groundwater reaches the well. Now, some of those contaminant -- I mean,
20 the contaminants can be diluted, but it assumes that all of it reaches
21 the well, okay, so that's the mass balance approach.

22 The nondispersion approach assumes that the well is at the
23 edge of the -- the downgrading edge of the contamination zone. When we
24 look at this same cross-section here, we've got the contamination zone;
25 the unsaturated zone, and the saturated zone, and this is contamination
here. Now, the big difference between these two, in addition to the
well location, in the nondispersion approach, not all of the
contaminants necessarily reach the well, and so, that's a big
assumption. And because of these differences here, you can get big
differences in terms of the concentration that you estimate based on

ADD
RIL
EY
&
ASS
OCI
ATE

1 these two approaches here.

2 So, I would look at these two, and I would say that these
3 are two different conceptual models. Now, the question is, well, which
4 one is right? I mean, if you know that your well is going to be at the
5 downgrading edge of the contamination, well, clearly, this one is the
6 correct one to use. I mean, if there are some physical limitations at
7 your site that will prevent somebody from putting the well in the center
8 of the contamination, you obviously want to use this approach here,
9 because you've got justification for using that.

10 Let's say you don't know that. I mean, there are no
11 physical limitations to prevent somebody from putting that well in the
12 center of the contamination area. The question is which one of these
13 should you be using? Now, the default is the nondispersion. So, if you
14 went in there and used that code without specifying, it's going to
15 automatically use this one down here at the bottom.

16 I went through and made a little plot here showing how the
17 -- showing the dilution factor that you get using the mass balance and
18 the nondispersion approaches. Now, this dilution factor here is the --
19 is a factor that -- the concentration that reaches the groundwater is
20 multiplied by this dilution factor. So this accounts for the dilution
21 that you get in contaminants reaching the groundwater. So, for example,
22 if you get a dilution factor of 0.5, the concentration reaching the
23 groundwater would be multiplied by 0.5. So you cut your concentration
24 in half, basically, what that number represents.

25 And the dilution factor of one means that you basically have
no dilution, because you're multiplying the concentration by one, so
you're not getting any dilution. You can see that if you use the mass
balance approach, it pretty much -- you get a dilution factor of one
when you get to 500 square meters, and this is the area of contamination
down here at the bottom. The area of contamination of 500 square meters

ADN
RIL
EY
&
ASS
OCI
ATE

1 gives you a dilution factor of one using the mass balance approach, and
2 this is using all of the defaults in RESRAD, and by the way, I'm not
3 advocating that you do that, but just for illustration purposes, I used
4 all of the defaults.

5 Now, at that 500 square meter area, where you get a dilution
6 factor of one for the mass balance approach, you get a dilution factor
7 of 0.6 for the nondispersion. So instead of getting no dilution, you
8 get a dilution of roughly 40 percent using the nondispersion, so just
9 simply running that code and not specifying which of those approaches
10 you're going to use for treating the groundwater would reduce your dose,
11 it would reduce your concentration in groundwater by 40 percent.

12 Now, it turns out that the groundwater is the dominant
13 pathway where you can get quite a reduction in your doses based on just
14 how you select the approach you're using for modeling the groundwater.
15 And so, what we would advocate here under this case here, that if you
16 didn't have any other data to support using one approach versus the
17 other, you should use the mass balance approach, because it's the most
18 conservative.

19 But as I said, if you've got some site-specific information
20 that will support using the nondispersion approach, then, you should use
21 that approach. But outside of having any other information, the one you
22 would want to use in this case would be the mass balance approach.

23 Now, assuming that you didn't know -- I mean, you didn't
24 have any site-specific information that would say, well, we should use
25 the nondispersion or the mass balance approach, one way you might be
able to get around this, if you know the area of your contamination,
then I would advocate -- and this is what we're advocating in the
technical basis document -- that if the area of the contamination is
greater than this ratio here, which is the ratio of the well pumpage to
the infiltration rate, what that gives you is that gives you a measure

ADN
RIL
EY
&
ASS
OCI
ATE

1 of the captured zone of the well.

2 And so, if the area of contamination is bigger than the
3 capture zone, then, obviously, some of the contaminants would not get
4 into the well, which is what is assumed under the nondispersion
5 approach, so a simple calculation like this might be adequate
6 justification to use the nondispersion approach. But you need to do
7 that, though. I mean, you shouldn't just use the nondispersion approach
8 simply because it's the default, because there may not be any
9 justification for it.

10 So, anyway, this concludes my presentation. I just tried to
11 walk you through some of the things that we're thinking about in this
12 part of the technical basis document, and I'll answer any questions if
13 any of you have any.

14 ROBERTS: Rick Roberts, Rocky Mountain Remediation Services.

15 In your example there, you have already assumed that
16 groundwater is a significant pathway and that you have to assess it. If
17 you move your conceptual model up one level, and you look at the
18 conceptual model for a site where you're looking at all pathways:
19 you're looking at soil ingestion, soil inhalation --

20 THAGGARD: Yes.

21 ROBERTS: -- all the different pathways, one thing that is
22 very important in that, I feel is very important, is that what that
23 tells you is your world of pathways that you need to assess. But it
24 kind of gives you a guideline, too, for telling which pathways may be
25 significant or insignificant or may be incomplete, and in this guidance
document that you're putting together, could you put in some guidance on
things that -- pathways you would consider to be significant where you
would probably need to quantitatively assess those, things that are
maybe insignificant where you don't need to quantitatively assess those,
maybe just discuss those, and guidance on what you would consider to be

ADN
RIL
EY
&
ASS
OCI
ATE

1 incomplete pathways? That way, what could be put together is a more
2 streamlined, quantitative assessment when you start looking at a site.

3 THAGGARD: Well, I do agree that you could probably
4 streamline the analysis, but I don't know if you can do that a priori.
5 I think you -- I mean, for example, if you -- depending upon your
6 initial conceptualization, it can influence which pathway turns out to
7 be important. Like, for example, just take the example here, where if
8 you use the nondispersion approach, for example, it may reduce your
9 groundwater concentration. That groundwater concentration may mean that
10 the groundwater pathway is not that important.

11 So, simply, how you initially -- the initial conceptual
12 model you come up with may influence what's important, which pathways
13 are important. So, I think the way we've kind of -- the approach we've
14 kind of taken in the technical basis document is that you really need to
15 just do the best job you can up front, describing all the pathways, I
16 mean, in terms of thinking about how you think those contaminants are
17 going to move at that site.

18 Now, you may be able to -- later on, during the subsequent
19 analysis, you may be able to screen out unimportant pathways and not
20 really give those much attention, but I think up front, in the initial
21 assessment, you really need to think pretty hard about what you're
22 trying to do.

23 ROBERTS: Okay; and I'll give you an example which clarifies
24 it in my mind, is if you've got a surface soil site, where you've got to
25 clean up surface soils, and of course, you're going to assess direct
ingestion, direct inhalation of those soils as well as you're going to
look at external radiation, but a pathway compared to that such as if
you're looking at wind dispersion to an adjacent water body, where you
have wind dispersed and deposition on the water body, and then, you've
got subsequent ingestion of water from that body, I would consider that

ADN
RIL
EY
&
ASS
OCI
ATE

1 to be an insignificant pathway and something that really should not be
2 quantitatively assessed and could be addressed up front as being an
3 insignificant pathway.

4 And that's the type of thing I'm looking at, is that things
5 where you really expect very little radiation dose that really, up
6 front, you could give a discussion and talk about the insignificance of
7 the pathway and really not have to quantitatively assess it --

8 THAGGARD: Okay.

9 ROBERTS: -- because it really will be an insignificant part
10 of the total dose.

11 THAGGARD: Okay; well, we'll think about that. That may be
12 a valid point.

13 ROBERTS: Okay; thank you.

14 THAGGARD: Any other questions?

15 PRICE: Joe Price again with SAIC.

16 In providing this example here, you are telling us that the
17 NRC would look favorably on some presentation of physical limitations
18 for justifying, say, location of a well.

19 THAGGARD: Yes, correct.

20 PRICE: So, if we had a cap and slurry wall around it, and
21 we could say, well, we're having a minimal amount of water moving
22 through our, say, buried waste, NRC might find that persuasive --

23 THAGGARD: That is correct.

24 PRICE: -- to say that the well is not to be located outside
25 that.

THAGGARD: That is correct.

PRICE: Is there any upper or lower cutoff on productivity
of this well so that we know how to quantify that?

THAGGARD: You mean where you can eliminate the groundwater
pathway altogether?

ANN
REL
EY
&
ASS
OCI
ATE

1 PRICE: So that you can eliminate the well usage pathway.

2 THAGGARD: Well, that would be the same thing. Yes, we
3 actually -- I think we are going to get into that a little bit in
4 another section of the technical basis document; in particular, we've
5 got a section that we're developing on establishing land use scenarios,
6 so that will probably be part of the land use scenario discussion, and I
7 don't know what that number is right off the top of my head, to be
8 honest with you, but yes, I think we are going to have something like
9 that in there.

10 PRICE: Thank you.

11 THAGGARD: Any other questions?

12 [No response.]

13 THAGGARD: Okay; if there are no other questions, then, I
14 guess I will ask my colleague, Dr. Codell. I guess he --

15 EID: Let's wait just a few minutes. He just went outside.

16 THAGGARD: Okay; he probably went to get some more copies.
17 Okay; here he comes.

18 CODELL: Thank you.

19 [Pause.]

20 CODELL: I apologize for being late. I managed to jam about
21 four copiers in a row trying to make copies this morning. I hope that
22 isn't like the rest of my presentation.

23 I'm Dick Codell. I spend most of my time doing performance
24 assessments at eye level. I also have been getting into the
25 decommissioning and other kinds of waste management problems lately.

I'd like to talk about the treatment of uncertainty in NRC
decommissioning. Uncertainty is inherent in all dose assessments and
everything else we do in life. We have to consider it in regulatory
& decision making. The three kinds of uncertainty: we have model
uncertainty and scenario uncertainty, and we just heard a talk from Mark

ADN
RIL
EY
&
ASS
OCI
ATE

1 about the first one.

2 Most of what I want to talk about is parameter uncertainty,
3 how we deal with -- once we've chosen the conceptual models, what do we
4 do with them? How do we evaluate the models? How do we evaluate the
5 results of the models in terms of the criteria?

6 We also recognize, in addition to these three sources of
7 uncertainty, we are not going to capture all uncertainty, nor do we have
8 to. Sometimes, we can get by just by being conservative.

9 The emphasis of the uncertainty analysis really is to
10 identify the important assumptions and parameter values that, unaltered,
11 could change our decision. Sometimes, along with uncertainty, we also
12 employ sensitivity analysis, which is a whole field of endeavor. I
13 don't want to get into it today, but it is a way that we can look at the
14 results and further decide which are the important parameters and how
15 they might affect the overall outcome in terms of our regulatory
16 decision making.

17 Okay; issues of uncertainty are on the next slide. So, we
18 use deterministic or probabilistic analyses. How do we address
19 uncertainty in models and scenarios? What is an appropriate design
20 criterion for probabilistic analysis, and how do we assign probability
21 distributions for use in our models? I'll cover all of these.

22 First, the -- I'd like to address the issue of whether we
23 should do probabilistic or deterministic analyses. Now, the agency, in
24 general, has been shifting toward doing more probabilistic analyses.
25 Probabilistic risk assessment has been used for many years in reactors.
We've been using it for well over a decade in high level waste
management. It's getting down to other areas of regulation a little
more slowly, but we are definitely considering it for all other
regulations as well.

Now, the arguments would be that a deterministic analysis

ADN
RIL
EY
&
ASS
OCI
ATE

1 has the advantages of being simple to implement and easy to communicate
2 to nontechnical audiences. These are big, positive factors, very
3 important factors. The disadvantages are that it doesn't allow
4 consideration of combinations of input parameters over wide ranges of
5 their possible values, and it doesn't provide information on the
6 uncertainty or the sensitivity to the parameter values, and in order to
7 make a strong case using deterministic analysis, you almost always have
8 to require pessimistic estimates of model parameters, usually leading to
9 overly conservative evaluations. Later, at the end of my presentation,
10 I have an example I'll go through with a realistic kind of analysis that
11 show these effects.

12 Next slide, I cover how do we address models and scenarios
13 of uncertainty, and Mark, I think, covered this adequately. We should
14 use conservative scenarios. We should consider alternative conceptual
15 models and use the ones most conservative but consistent with the site
16 data.

17 The next question, the next issue was what is an appropriate
18 decision criterion? Well, first, I'll cover deterministic analysis.
19 This figure illustrates that we have a model that depends on N different
20 parameters, and we can sample a value of the parameter from each
21 distribution and then calculate a dose distribution. For doing a
22 deterministic analysis, what we would want to do is pick a conservative
23 value of the parameter, of all of the parameters.

24 However, this isn't always clear, but it is -- you don't
25 know whether a high value or a low value would be conservative, or in
some rare cases, it might be in the middle somewhere, so you may not be
able to a priori pick the worst -- the most conservative value of the
parameter. But let's say we could. We would pick, say, the value
that's at the 90th percent or the 10th percent of the dose curve,
whether a low value or a high value was more conservative; plug those

ADN
RIL
EY
&
ASS
OCI
ATE

1 into our model, and then, we would get a single result, which would be
2 probably at the extreme tail of the correct distribution, and this would
3 be our result using a deterministic analysis.

4 This would be okay as long as we -- as long as it meets the
5 criterion. If it doesn't, then, we have to back pedal.

6 So, the alternative to doing a deterministic analysis, of
7 course, is to do a probabilistic analysis. The next slide illustrates
8 what is involved in a probabilistic or a Monte Carlo analysis, being one
9 of the kinds of probabilistic analyses you can do. You would have your
10 different distributions, which you would represent by various shapes and
11 ranges, and then, you would stochastically or randomly sample from each
12 distribution one time. Then, with those set of values you've picked,
13 you would run those through your code, through your conceptual model,
14 and then, you would get one output. So, you would have an input, which
15 we call a vector, and an output dose. You would repeat this, then,
16 typically hundreds to thousands of times to get an output dose
17 distribution.

18 Once you have that distribution, the next question is how do
19 you treat it in terms of the regulatory criterion? The regulatory
20 criteria are usually fixed values, such as 25 millirem dose, don't
21 exceed 25 millirem dose. That's a fixed criterion. However, you have a
22 distribution which some of the values of which may exceed that limit.
23 So, you don't want to penalize yourself too severely. So, what do you
24 pick as the metric of that distribution to compare to the criterion?

25 Well, here, I start talking about what we do. We use the
Monte Carlo analysis to generate this distribution, and then, we
consider what the metric is of the output dose distribution. We can
calculate the -- two possibilities that -- two main possibilities are we
& look at the -- for each output, we have a dose versus time curve. We
can calculate -- we can take the peak from each one of those curves and

ADN
RIL
EY
&
ASS
OCI
ATE

1 then take its mean, or we can take the average of all of the curves
2 together and take the peak of the average. We call that the peak of the
3 mean versus the mean of the peak, and if that's confusing, that's what
4 it was intended to do.

5 [Laughter.]

6 CODELL: Let me show a picture here. This is from the
7 example that I will illustrate later in more detail, but this is actual
8 output from that example. What we have here, faintly, this was a run
9 that had 1,000 runs in it, 1,000 Monte Carlo runs in it, each sampling
10 from the input distributions. I show 10 -- the first 10 outputs from
11 this run, and each one of these is this faint, dotted curve. Now, each
12 one of these curves has a peak. That's these dark circles here, and
13 there's 10 of them.

14 So, if you take the average of all of the peaks for the
15 1,000 runs, not 10 here but the 1,000, you would get this value, this
16 dotted line here for the value. Now -- and this heavy curve down here
17 is the average of all the 1,000 dose versus time curves, and its peak is
18 considerably lower. It's about here. So, here, we have the comparing
19 the two possible criteria: the mean of the peaks or the peak of the
20 mean for a typical example. That's just for illustration but to make it
21 a little clearer later.

22 Now, to go a little more in depth into the discussion about
23 the -- which one to choose, first, let's look at the mean of the peak,
24 the peak doses. If we take all of the Monte Carlo results and take
25 their mean, that's that heavy curve on the previous figure. No, I'm
sorry; the other way around; the mean of the peak doses. This is the
first one. You take the peak dose from each of the 1,000 runs, and you
take its mean. The advantage of this is that it's conservative. You
& saw that the one way of calculating it was higher than the other. It's
OCI conservative, and that's always the case. It couldn't be higher. It's
ATE

1 always higher than the other way.

2 And the regulations, it seems that the consensus of the NRC
3 regulators is that the regulation clearly states that the criterion is
4 the peak dose, and that doesn't say for the average of all; it seems to
5 refer -- the wording in many of the regulations is that it's the peak
6 dose, and that's the peak from each of the Monte Carlo runs, and it's
7 relatively easily understood. This advantage, though, is that it always
8 produces a higher dose when you do it this way, because it allows you to
9 arbitrarily take each one of the runs, superimpose them on each other,
10 and this is maybe a little bit illogical, because if you have two runs,
11 and one gives you a peak at 100 years, and one gives you a peak at 300
12 years, you're talking about two different people, and it's not the same
13 person getting the dose, so you're artificially raising the dose this
14 way.

15 The peak of the mean, we take the average of all the dose
16 versus time curves and then take the peak of that dose, has the
17 advantage of being consistent with the proposed regulations for the high
18 level waste repository, 10 CFR 63, which is going to hit the streets any
19 day. It also treats the uncertainty more fairly in terms of risk to a
20 member of the exposed group. That is the main reason we chose it for
21 the high level waste criterion. And it considers only doses that could
22 occur in a person's life span. You're not talking about two different
23 people eventually. It's always the dose at any given time, the mean
24 dose at any given time in the evaluation period. So it's always
25 referring to a single person.

So, those are the two criteria that are under consideration,
and word has it that they will probably go with the more conservative
one, but I think it's worth bringing it up in a meeting like this if
there is anyone who feels differently about that.

Other considerations in picking a criterion for

ADN
RIL
EY
&
ASS
OCI
ATE

1 probabilistic analysis are instead of picking -- I mean, why do we pick
2 the mean? Why don't we pick something more restrictive, like maybe the
3 90th percentile of the dose distribution that you get from the Monte
4 Carlo analysis? The advantage of that would be you have a high
5 percentile, 90th percentile, gives a higher confidence that the dose
6 limit won't be exceeded, because you know you have a lot of uncertainty
7 in your analysis. You may not be capturing it all, and this makes the
8 public feel better about it.

9 And also, the high percentile criterion like 90th percentile
10 would guard against risk dilution, which is a term applied to Monte
11 Carlo analyses where you might have overly wide input distributions,
12 because you don't know your values very well, and so, you've picked wide
13 distributions, and this maybe underestimates the risk, but if you pick a
14 high percentile, you're likely to capture the -- anything that might
15 have had risk dilution associated with it. Disadvantages, though, of
16 picking, like, the 90th percentile is that the mean has a basis in risk,
17 but the 90th percentile doesn't necessarily.

18 And because the dose results from Monte Carlo analysis are
19 generally skewed by a few large values, and therefore, the mean already
20 is a high percentile, and you'll see that in the example I'll cover
21 later, the mean is almost always greater than the 50th percentile for
22 these kinds of distributions.

23 Okay; now, the next thing I'd like to cover is how we might
24 go about assigning probability distributions for Monte Carlo analyses.
25 Here are a few general guidelines. The distributions generally reflect
the degree of belief that the true but unknown value lies within the
stated range. That's where we're dealing with in general here. Now,
there's another consideration. There's spatial -- for example, values
that are -- there is a true difference between the value of a parameter
between one side and the next. The reason? Even within different

ADN
RIL
EY
&
ASS
OCI
ATE

1 places within the same site or the value changes with time. This is
2 often grouped into uncertainty, but it isn't uncertainty. It's
3 something else, and I can't get into a lot of details, but just bear in
4 mind there is this problem between the two kinds of uncertainty, but
5 we're generally dealing with the first kinds. We'll try to keep it
6 focused on that.

7 We should generally avoid overly restricted ranges that
8 reflect unwarranted precision in our data, because generally, our data
9 is pretty poor; sometimes, nonexistent, and we should, by the same
10 token, avoid overly broad ranges that could cause risk dilution. It has
11 a tendency of making wide distributions when you don't know your data
12 very well.

13 Okay; now, some more of the guidelines: we don't have to
14 sample every variable that goes into the model. We can just select the
15 important ones that need to be sampled. We can often determine this by
16 doing iterative analyses; that is, we'll do a rough first analysis, and
17 then, we'll see which are the variables that tend to stick out
18 prominently. We cannot always do this, and there's a lot of danger
19 involved in doing that, so you must be careful not to discard variables
20 that don't seem to be important, but that may be an inadequacy in your
21 model.

22 Now, if you -- once you've decided on the list of variables,
23 you would assign distribution to the important variables, depending
24 generally on the quantity of the available data. If you have lots and
25 lots of data, you can take those, and you can just simply plot it up and
get an empirical distribution that you can plug right into your model.
Here's an example of something like rock bulk density, which is
something where there is a lot of data on. You can just put it exactly
and get a .pdf. That's rarely the case.

If you have somewhat less data, you might be able to fit it

1 to a standard distribution; that is, you might say it fits a normal
2 distribution or log normal distribution and then get a distribution to
3 plug into your model that way. If you have some but by no means
4 sufficient data, you can supplement it with other kinds of data; for
5 example, there may be a physical basis for the shape of the distribution
6 that you may be able to attach to some mechanistic model of the data.

7 Or, you may know the data not too well at your site, but on
8 a regional basis, you would know that the data are distributed a certain
9 way, and you can use that. You can take that data from a regional or a
10 wider area, and you can update it with -- you can take the non-site
11 specific data, and you can update it with a few site data, and this is
12 generally known as Bayes Theorem. Bayesian updating is another word for
13 it. They're not things we can get into in any detail here.

14 If you have insufficient data, even less data, you may be
15 able to take other data that are not the same data and infer the
16 results. For example, if you know that root uptake data, you may be
17 able to estimate KD, equilibrium coefficient in soil, what you would use
18 in your retardation part of the calculation. This is frequently done.
19 If all you know about your data are a few key pieces of information, and
20 you don't have anything to fall back on, you can -- the best you can do
21 is to pick an unbiased distribution. There are certain statistical
22 theories of data, one of which -- probably the best well-known is the
23 maximum entropy formalism, which says that in order to -- the
24 least-biased estimator of your data is based on a few rules that
25 involves in maximizing the informational entropy.

And this is in a textbook by Milton Hart that's a well-known
textbook, and it's based on a guy's work named Shannon, and he called
his work informational entropy. For example, here are two examples of
what it does. If you only know the range of the data, this is obvious;
if you only have two points, the upper and the lower, you would pick a

ADN
RIL
EY
&
ASS
OCI
ATE

1 uniform distribution between those two values. If you knew only the
2 mean and the standard deviation, you would pick the normal, and you can
3 prove this mathematically that these are the least-biased estimators of
4 your input distribution.

5 Okay; now, the next point in picking distributions and
6 running Monte Carlo codes is to take into account parameter
7 correlations. For example, you have two variables that are used in the
8 result, A and B, and they're obviously correlated, so when you're
9 sampling your Monte Carlo values, you want to make sure that you capture
10 this correlation. You don't want to pick a value of A here and a value
11 of B that's not correlated to it, because you may end up with a bad
12 combination, which won't serve you well. For example, suppose you have
13 -- you know that hydraulic conductivity and hydraulic gradient would be
14 coupled, obviously, because otherwise, you could have a very large or a
15 very small flow, and if you don't take proper account of those
16 correlations, you may end up picking something that's bizarre. So,
17 these are built into Monte Carlo kinds of sampling routines that we use
18 all the time.

19 And now, I'd like to go through a simple example. This very
20 simple example is of a -- you have a -- this is looking down on a
21 groundwater situation, where you have a release at a point of a quantity
22 M of the radionuclide, and it is transported down gradient in direction
23 of flow, and it spreads out into a plume. It is also retarded and then
24 is consumed at a user's well. The parameters of the system are the
25 quantity M; the velocity of the groundwater U, the thickness of the
aquifer, the dispersivities in the X and Y direction; the retardation
and the effect of porosity, the seven parameters.

ADN
RIL
EY
&
ASS
OCI
ATE
I put -- the absolute values, of course, aren't important,
but I just -- so you could follow it better later on if you wanted to, I
put the values I used in the table and also equations I used to

1 calculate the doses on the next page. But like I said, these are not
2 particularly important.

3 What I wanted to show for this example, and it probably is
4 somewhat more sensitive than a real example, is that you would get
5 different -- very different conclusions from looking -- choosing the
6 different ways of calculating the result and the different criteria.
7 So, this is a rather busy slide that has everything on here that I
8 wanted to show. Let me go over it.

9 This is a cumulative distribution of the results from 1,000
10 runs using that Monte Carlo example, and so, it's a plot of the dose on
11 the X axis versus the cumulative probability of being exceeded on the Y
12 axis. Now, what you see here is -- what I'd like to show is that if you
13 chose the mean of the peak doses, you would get a high percentile, in
14 this case, 71st percentile, of the distribution. So, this is somewhat
15 -- takes into account that we want to pick a high percentile for
16 satisfying the intended audience that the site will comply.

17 Now, if you took the -- if you did only a deterministic
18 analysis, and you chose your parameters of the analysis and just so you
19 could do one calculation, and you chose the 90th percentile worst value
20 of each of the seven distributions, you would end up with a result that
21 is way, way out here on the tail. It's much, much higher than the dose
22 which you would get from the other criteria. The two main ones that we
23 talked about were the peak of the mean dose, which is the smallest dose
24 and the one that's closest to the risk and what we're using in
25 high-level waste regulation. That's way down here. The mean of the
peak dose, which is quite a bit higher but is still reflective of all of
the distributions of the data versus the deterministic result, which is
way out here, so you're penalizing yourself by doing the deterministic
analysis.

So, I'd like to conclude. We must take uncertainty into

ADN
RIL
EY
&
ASS
OCI
ATE

1 consideration in all of the regulations. The deterministic analysis is
2 acceptable, but you must demonstrate that it is conservative, and that
3 may be very difficult to do. We must consider alternative conceptual
4 models and justify those choices. Probabilistic analyses are generally
5 less conservative. Distributions of parameters for the Monte Carlo
6 analyses should be chosen carefully and based on as much site data as
7 possible.

8 And there are several metrics for the criteria for
9 calculated dose that we're considering: mean of the peak dose; peak of
10 the mean dose; and some percentile larger than the median, say, the 90th
11 percentile.

12 Thank you for your attention. Any questions?

13 POTTER: Yes; Tom Potter, Radiation protection consultant.
14 I'm intrigued by the peak of the mean doses approach. Do you mean to
15 say peak of the mean doses where mean is over a 70-year period or
16 something like that, a lifetime period?

17 CODELL: Well, let me put that slide back up, and I'll try
18 to explain it, that it's caused a lot of confusion. Finally, it sinks
19 in eventually. I don't blame you for being confused. This example
20 here, it's a very simple thing to calculate. We have these 1,000 runs,
21 and we just pick an instant in time, say, 500 years, okay, for example.
22 Then, we take, at the 500 year time, we take the average of all of the
23 1,000 doses from the 1,000 runs, and that's the mean curve. So, it
24 would be at any time over the whole 1,000 year period.

25 POTTER: And, in other words, the contribution of one
realization, say, where you don't have any dose at all up until the year
2000, in which case you have 20,000 millirem, the contribution of that
realization is 10 millirem.

CODELL: Zero; well, I mean, the contribution of that would
be zero if it's zero.

ADN
RIL
EY
&
ASS
OCI
ATE

1 POTTER: Up until the last year. Then, you have 20,000
2 millirem in the last year.

3 CODELL: Yes, but that would be averaged over 1,000. You'd
4 only -- it would only have a weight of one-thousandth for the total.

5 POTTER: But I'm only talking about the contribution of that
6 one realization. You're looking at the whole integration.

7 CODELL: Right; well, you see, each realization will have a
8 weight of $1/N$, where N is the number of realizations. So, if it does
9 have a very large peak, like this one has a very large peak, but it only
10 has a contribution of one-thousandth, because there are 999 other
11 realizations, so it doesn't affect the result that greatly, so you don't
12 see it reflected here.

13 EID: Can I just add more to explain this? I guess in the
14 process, you have different realizations, and each realization will
15 calculate the peak dose for within 1,000 years, because in the rule, we
16 say that you should calculate the dose up to 1,000 years. That's the
17 compliance with the decommissioning. In high-level waste, it is 10,000
18 years. So, for each realization, you calculate the peak dose within
19 1,000 years.

20 POTTER: The peak of the means. Well, I may need to talk
21 with you a little bit separately outside, then. It sounds, though, that
22 in this respect, NRC is gravitating a little bit more toward the EPA
23 approach of lifetime risk-based regulation rather than individual year
24 dose regulation, which I think is probably a good thing overall.

25 CODELL: It is a good thing, but there are a lot of people
who favor the other approach because of its conservatism, but even
though it's a significant difference, I'm not sure it would make a lot
of difference in actual results. Even in this example, which I think is
probably more severe than typical, it makes about a factor of four
difference. In the high-level waste regulation, as it turns out, it

ADN
RIL
EY
&
ASS
OCI
ATE

1 makes almost no difference.

2 POTTER: Okay.

3 EID: I would like to add that also, the decommissioning
4 rule requires to look for the annual peak dose.

5 POTTER: Yes, I understand that.

6 EID: Of the mean dose, and that's the difference.

7 POTTER: Yes.

8 EID: Between, you know, the high-level waste and the
9 decommissioning. So, in a way, you know, the explanation currently to
10 look at the annual peak dose, so if we deal with the mean dose, this
11 means we are not treating the peak dose.

12 POTTER: Yes, I understand that -- right, but we're not
13 there with this right now.

14 CODELL: We were cognizant of the fact that the high-level
15 waste regulation is stated differently. We were trying to make sure
16 that there wasn't a regulatory conflict among the various parts of the
17 NRC waste regulations.

18 POTTER: Yes; I have considerable experience in
19 probabilistic risk assessment in the reactor area. I spent about 10
20 years in that back when it was popular and
21 I --

22 CODELL: When reactors were popular.

23 [Laughter.]

24 POTTER: Both. I have -- and it has its advantages,
25 particularly in a technical setting or a setting of technical people. I
wonder -- well, I don't wonder; I have a serious concern that it's going
to be a seriously conflicting problem with one of NRC's other
initiatives, which is to increase public involvement, because one of the
things that you can best do to gunk up any kind of public discussion of
things is to drop in a probability distribution.

ADN
RIL
EY
&
ASS
OCI
ATE

1 CODELL: Right.

2 POTTER: And that's a real problem that I see we're going to
3 have to wrestle with if we're going to pursue this very far in this kind
4 of regulatory setting. You can get an example -- my experience is that
5 the public is very comfortable with binary thinking and particularly
6 binary thinking phase zero, which is radioactive material is bad, and no
7 radioactive material is good. It takes considerable movement on the
8 part of the public to get to the point that some radioactive material
9 may not be so bad, and a lot of radioactive material is bad.

10 But to extend that to any kind of comprehension of real
11 probabilistic assessment is very problematic. I think it's particularly
12 problematic when we're focusing the probabilistic assessment on one part
13 of the analysis, specifically parameter analysis, and in a sense, I
14 think we're portraying a picture to the public that we have -- that the
15 picture we're presenting here is the whole picture, and it's going to be
16 very difficult to explain to the public that we've left out a whole
17 range of the picture down here that doesn't matter to us, because it's
18 not important from the standpoint of compliance with regulation, but
19 we're focusing on these scenarios that are pretty much
20 conservatively-defined scenarios, but we're really interested in our
21 uncertainty and understanding of uncertainty about those conservative
22 scenarios.

23 I don't have an answer to that question but if you're really
24 interested in pursuing this, I think we're going to have to have some
25 way to address that qualitatively or pictures or somehow.

CODELL: That's another difference between this proposed
regulation and the regulation of high-level waste repositories. There,
we explicitly account for range of scenarios and conceptual models
wherever we can explicitly in the PRAs.

POTTER: Yes; I don't see anything in this regulation that

ADN
RIL
EY
&
ASS
OCI
ATE

1 prevents that for the decommissioning.

2 CODELL: Well, I'm not sure -- I think it does.

3 THAGGARD: Well, there's nothing in the regulation that
4 prevents it. I think we tried to stay away from that, because usually,
5 to try to quantify the uncertainty in scenarios and things of that
6 nature, you get into the need for expert elicitation, and it becomes --
7 it can get to be really muddled. The parameter -- calculating the
8 uncertainty in the parameters is something that we felt is doable.
9 We're not saying that we -- we're not recognizing the uncertainty in the
10 other components of the analysis, but certainly, we can calculate the
11 uncertainty in the parameter.

12 And if it was a fairly easy process to do with the
13 scenarios, we would probably be advocating something for the scenarios,
14 too, but in the high-level waste program, where you're only dealing with
15 one repository, it's much easier to bring in experts and get people to
16 agree or disagree on the probability of scenarios and models and things
17 of that nature.

18 CODELL: Right; it helps to have tens of billions of dollars
19 to dispose of.

20 THAGGARD: When you're dealing with a decommissioning site,
21 where you may have one licensee, we felt that advocating that they try
22 to quantify the uncertainty in the other aspects of the analysis may be
23 too much of a burden. We're not disagreeing with your assessment, but
24 we're recognizing that there are some differences in the programs, and
25 we're trying to be a little bit pragmatic about it.

POTTER: Well, that's desirable, and I wouldn't discourage
that.

There is one other aspect to this, and that is that the
distribution data that we have to work with is usually not very suitable
to our needs, and I'll give you a case in point. The outcome is I

ADN
RIL
EY
&
ASS
OCI
ATE

1 believe that our uncertainties in our dose assessments are less
2 important and smaller than we commonly think by running these kinds of
3 probabilistic assessments. For example, consider a situation where root
4 uptake is important. We have distributions of root uptake. Generally,
5 those distributions represent half-kg samples or 1 kg samples, things
6 like that. They may come from all over the country. But even if you
7 have them from one site, they're highly variable, and we take those; we
8 calculate the standard deviation on that basis, and that's what we use
9 in our input distribution.

10 But a person who has a garden doesn't need a half a kg a
11 year. He needs maybe 10 kgs a year. What we're interested in is not
12 the variability in the half-kg samples. We're interested in the
13 variability in the 10-kg lots. That variability is going to be much
14 smaller than the variability in the half-kg samples. Not only that, but
15 I think it's by the central limit theorem, that variability is going to
16 be much closer to normal, normal distribution, than whatever the
17 underlying distribution of the half-kg samples was. We don't do
18 anything about this, and we don't really have much of a way of doing
19 anything about it in the analysis. As a result, what we do is we
20 overstate the variability in our analysis.

21 CODELL: I think you could take that into account, Tom.

22 EID: I would like to add two things: that NRC is trying
23 also to help the licensees. They are tending to go to probabilistic
24 analysis, and because we are developing version two code, which is more
25 probabilistic than D&D code, the new one that's coming, and also, we are
supporting development of RESRAD probabilistics, so the licensee could
use that version when it is ready. So the process, I expect to be not
as difficult as we think, although yes, I agree that it takes some time
for understanding all of the probabilistic approach.

So, I expect my perception that for the next one or two

ADN
RIL
EY
&
ASS
OCI
ATE

1 years that probabilistic could be routine as running RESRAD, which is
2 deterministic.

3 EID: The NRC could still deterministic. If they want to
4 come and use deterministic, that's fine, but as Dick showed, when you
5 run deterministic, you are going to the risk of being highly
6 conservative, and the staff will try to review to make sure that you are
7 highly conservative. So, it is, you know, it is the choice of the
8 licensee whether to go to deterministic; still, they go that; they could
9 take that route or to go to probabilistic.

10 POTTER: Well, I think we will be helped if we keep in mind
11 the fundamental goal here, and I'm speaking now for probably a few dozen
12 sites where there is relatively low concentration of radioactive
13 material. We don't want to make the wrong decision, or we want to make
14 sure that if we make the wrong decision, we make it only rarely, and if
15 we do make a rare wrong decision, we don't want it to be one with big
16 consequences.

17 I think we have some protection in that regard with the kind
18 of sites we are dealing here that are the most problematic; that is to
19 say, high volumes of material, low concentration, and I think if we keep
20 that in mind and also keep in mind the fact that the NRC has regulated
21 with considerable success, I believe, for the past several decades with
22 minimal use of probabilistic approaches in this regard, I think we can
23 work these problems out.

24 MORTON: Henry Morton.

25 If I understood correctly in the inputs, source term is one
distribution that you would input that's treated probabilistically.
Now, if that's the case, and you pick something like the mean of the
peaks and get a reasonably conservative derivation of the DCGL with this
approach, and then, in the final status survey process, where we apply
statistics to get conservatism or, that is, a high probability of

ADN
RIL
EY
&
ASS
OCI
ATE

1 compliance with that DCGL, on the other end of the problem, when we come
2 to mesh these, it seems to me that we're really compounding the
3 conservatism in the decision of compliance.

4 EID: I think the answer to this question, to have a fair
5 comparison, if you compare what we do now and what is proposed, what we
6 do now to go to deterministic to derive the DCGL also of the licensees
7 and try to be conservative, and Dick here demonstrated that when you
8 pick the deterministic approach, so, you will be much, much more
9 conservative than selecting the mean of the peaks, and this is the
10 derivation of the DCGL. So, it's both ways you will be compounding
11 these two together when you do the survey. And that's what we are
12 talking about, which approach, deterministic, which is highly
13 conservative, and then compounded also with the conservative approach in
14 the survey or picking the mean of the peaks and then do the survey,
15 because in both ways, you derive the DCGL, and we are now trying to
16 compare which approaches to pick.

17 MORTON: My only point is that that argues against needing
18 to be overly conservative on both ends, so, recognition that there is
19 conservatism in both parts that compounds itself is the point.

20 EID: Yes; I think we discussed that before in the previous
21 workshops, and we understand that, and it is one of the areas that there
22 could be some kind of review by the staff to see what kind of
23 compounding of conservatism when you do the survey, but, you know, here
24 in this case, specific example that we are giving about talking about
25 the uncertainty, where actually, now, we are reducing that conservatism
when you go and try to be deterministic and to be overly conservative.

MORTON: Yes, relative to deterministic, sure.

EID: Right.

THAGGARD: And that's one of the points I want to add is,
actually, that's one of the reasons that the agency is moving more

ADN
RIL
EY
&
ASS
OCI
ATE

1 toward the use of probabilistic analysis is the recognition by the
2 commission that typically, when you do deterministic analysis, they do
3 have to be fairly conservative, and they typically wind up being awfully
4 conservative, and so, the commission is advocating the use of more
5 probabilistic analysis to reduce some of the conservatism. So, the
6 alternative is, like Bobby's saying, just use deterministic analysis and
7 everybody be, you know, way out on the end.

8 CODELL: When I worked in reactor licensing, I'm aware of
9 the deterministic kinds of calculations, and for those particular
10 calculations, they were very, very conservative. They were out in the
11 very extreme ends of the curve, and that attests to the overall good
12 safety record of the reactors in this country.

13 EID: But I would like to add, I mean, in certain cases for
14 deterministic, some people, they may come and just use RESRAD default
15 values, and they may say that we are conservative. It does not mean
16 that. What we mean that when you try to pick up the values, the
17 parameters when you do deterministic, they need to be conservative. For
18 example, if you try to look at values that you did not determine for the
19 site, so, we need to go and be conservative by KD values. If you do not
20 determine KD values, and you do not want to go and spend lots of money
21 for determining KD, maybe you need to assume that your soil is sandy
22 soil, which, possibly, if the groundwater pathway is the most sensitive
23 one, could be the most conservative one.

24 MORTON: I'm certainly not arguing in favor of
25 deterministic. For those cases for which probabilistic approaches are
useful, I'm in favor of being able to use it.

With respect to the graphic that's displayed, I'm wondering
-- it isn't entirely clear to me what was sampled to produce the various
data points; that is, what was varied and what was sampled? Do you have
multiple samplings of the distributions at each of the time periods?

ADN
RIL
EY
&
ASS
OCI
ATE

1 CODELL: Let me put this slide back up.

2 MORTON: Or do you vary the scenarios?

3 CODELL: There was only this one scenario. We're not
4 looking at different scenarios. Now, there may be a semantics problem
5 here. Some people call scenarios just a different set of parameters.

6 MORTON: No.

7 CODELL: If we have one model like that simple case of the
8 discharge in the well, here, we have -- here, we have the input
9 distributions of the seven variables that are in that model. This is
10 just a cartoon, but -- and we have a distribution of each one of the
11 input variables. For a single run, we would pick a random value from
12 this distribution, say this value for this variable; this value for this
13 one; this value for this one and go through them all and then take those
14 seven values; run it through the model and get a dose versus time curve.

15 Then, we go back, and we repeat this 999 more times, picking
16 random values from each of the distributions.

17 MORTON: Okay; that helps to clarify it. So, because I
18 think in terms of sampling as the choice of one value of each of those
19 input parameters, and when you feed that to the code, and the code
20 operates over time.

21 CODELL: The code does operate over time, but we're doing
22 1,000 calculations. We're doing it 1,000 times.

23 MORTON: Is it 1,000 samplings?

24 CODELL: 1,000 samplings of the parameters.

25 MORTON: In one run?

CODELL: No; 1,000 runs, too, of the code.

MORTON: Okay; how many samplings, then, per run?

ADN
RIL
EY
&
ASS
OCI
ATE

CODELL: One sample per run, because there are only seven
parameters. We sample the input values of these seven parameters; plug
them into the code; run it to reduce a dose versus time; then, go back

1 and do another sample of the seven values.

2 MORTON: Okay.

3 CODELL: And repeat that 1,000 times.

4 DARMAN: Darman from Nat-Yankee.

5 I guess I have a couple of questions. One on that slide:
6 you said something about if the variability really is due to spatial
7 differences or something, it's like, say, KD; now, there's a different
8 kind of rock over there than over there or something, and this really
9 isn't the right way to go.

10 CODELL: No, this is also the right way to go. It's just --
11 the model becomes much more complicated. I'll give you an example.
12 There is groundwater models that are called stochastic groundwater
13 models, where you -- they're two or three-dimensional models, and
14 instead of picking one value of hydraulic conductivity or the other
15 parameters that applies everywhere, you know that they're going to vary
16 from place to place within the model because of the variability in the
17 soil and the rock. So, these models go through, and they generate
18 random values of the model parameters within a given run, and these
19 values within a given run, say, hydraulic conductivity, vary from place
20 to place, and they're tied together by other rules like correlations,
21 spatial correlations, which you can get from the field using
22 geostatistical techniques.

23 But these are very complicated kinds of models. What we're
24 talking about here is, in general, sampling a single value to represent
25 the whole body of knowledge about your situation. You can do that. It
isn't -- you should recognize that this is a real phenomenon of spatial
variability, but you can still come up with a single representative
value that, for the purpose of making your calculation, may be good
enough. And the other kind, the other approach, is so difficult and
esoteric that it isn't employed very often except in Ph.D. dissertations

ADN
RIL
EY
&
ASS
OCI
ATE

1 and a few other cases.

2 DARMAN: So, I guess -- let me see if I understood that. KD
3 really does vary --

4 CODELL: Yes.

5 DARMAN: -- due to spatial differences, but we could figure
6 out what that distribution is or the max of it and the minimum or
7 whatever; plug that into the D&D code --

8 CODELL: Yes.

9 DARMAN: -- and it would be okay to run it that way.

10 CODELL: Yes; I'm not saying it's easy to do. It isn't easy
11 to do. But practically, that's what you would do, and you would hope
12 that you would capture the variability in your sampling of the true
13 variability, but the two things are different. You can, if you did,
14 say, 1,000 runs, you could pick a different value of KD for each run by
15 sampling it randomly, and you would hope that by sampling randomly, you
16 would be capturing the true variability in the spatial variability as
17 well, so that the value you're actually plugging into any given model
18 run is a representative value that captures all of the other kinds of
19 variability.

20 This is easier said than done, and you can prove this kind
21 of variability mathematically, and there are some cases that you can
22 deal with it; other cases, you -- it really doesn't make any sense to do
23 that, and those are very esoteric issues of spatial variability. For
24 practical reasons, you have to live with generally just picking a single
25 value of KD. Hardly anyone does any different in these kinds of
performance assessments. Even in the high-level program, we're stuck
with that.

ADN
RIL
EY
&
ASS
OCI
ATE
DARMAN: I guess that maybe is my next question: how does
all of this relate to that probabilistic overlay or whatever you're
talking, whatever you call it for version two of the D&D Code? Because

1 I think in that, you can put in a range for KD, right?

2 CODELL: Right; in fact, the D&D Code, as far as I
3 understand it, the version two, does exactly this.

4 DARMAN: So, you do put in the input distributions and if
5 they're varying over space or whatever.

6 CODELL: Well, not over space but over the sample
7 distribution.

8 [Pause.]

9 CODELL: I'm sorry; it's hard to explain it any better, and
10 it's not a very satisfactory explanation.

11 THAGGARD: Well, either way, you're putting in -- whether
12 you're sampling it, or you're putting in a single value, it's going to
13 be -- it's not varying spatially in the model.

14 DARMAN: No, not in the model. What I'm saying, you take 10
15 samples, one in that corner of the room, one in the center, all over the
16 place in this room, and you get 10 different results for, I don't know,
17 KD.

18 CODELL: Yes.

19 DARMAN: And maybe they really are -- you know, they are
20 varying, because there's different rocks in different places, but in
21 this new version, you can take, like, the lowest value we've got and the
22 highest value; somehow plug that in there, and it's going to run
23 through.

24 CODELL: But it's not going to capture that problem of the
25 value being spatial, spatially varying. Within a given run, one single
run, you'll only have one value of KD, for example.

DARMAN: Right.

CODELL: Because that's all the code can accept.

DARMAN: Right.

CODELL: So, the trick is to pick the value, the single

ADN
RIL
EY
&
ASS
OCI
ATE

1 value, that represents, as far as your model is concerned, all of the
2 data that you know about, and that's a very difficult problem, actually.

3 DARMAN: And not run -- so you're saying not run the
4 probabilistic version.

5 THAGGARD: Well, you could run the probabilistic version.
6 The question is coming up with a representative value to plug into that
7 code, whether you run it in a Monte Carlo mode, or you run it in a
8 deterministic mode. You've got to come up with a value that's
9 representative of the particular part of the site that you're analyzing.
10 You've got to come up with a representative value.

11 DARMAN: But if you run it deterministic, you come up with
12 one value; if you run it in the Monte Carlo way, don't you have to input
13 some kind of -- input the range somehow?

14 THAGGARD: If you run it in a Monte Carlo, you do have to
15 input a range. The range that you would be inputting would be your
16 uncertainty about that representative value that -- that one
17 representative value that you're using in your analysis. Now, what does
18 that represent? That one value should be based on data that you've
19 collected over the site is another issue. But the answer to -- I mean,
20 I think the answer to your question is that you can -- you can run a
21 distribution; I mean, you can simulate a distribution of KD values in
22 D&D. Now, how you determine that distribution, whether you base it on
23 different values you've collected over the site is another issue,
24 because it gets into the issue of how representative those different
25 values are in terms of what you're trying to model.

So, I think this relates to the question you were talking to
me about yesterday, and we probably need to maybe talk about this a
little bit separately.

CODELL: You would be generally wrong to take the values
that you've collected over a site for different values of KD and base

ADN
RIL
EY
&
ASS
OCI
ATE

1 your input distribution to D&D on those values. The problem is what
2 your distribution based on the values you'd be collecting on the site
3 are the spatial distribution of real variations from place to place.

4 DARMAN: Right.

5 CODELL: That's not the value that the code is using. The
6 code is using a representative value that somehow captures all of those
7 data but is not those data. It's some sort of an average.

8 DARMAN: So, if you had one type of rock, and you took 10
9 samples right at that place or sand or whatever; you came up with a
10 range of KDs from that --

11 CODELL: Yes.

12 DARMAN: -- that would be okay to plug into the code.

13 CODELL: Well, if they all came -- no, no, they wouldn't,
14 no, because that's mixing the two kinds of uncertainty. That's the
15 point I was trying to get at early on. We're talking about our degree
16 of belief in a real but unknown value of the effective KD for the whole
17 site. That's different from the variability in KD from place to place.
18 They're two different things, and so, what we really want are the
19 distribution in our degree of belief of the value, the effective value
20 of KD that the model uses, not the variation in place to place. So,
21 unfortunately, even if you have a lot of data on your site -- well, if
22 you have a lot of data on your site, you don't have to even do a
23 probabilistic analysis. You can do one analysis. But if you're trying
24 to do a probabilistic analysis, that's not what you want. You don't
25 want the variation of all of the data. That's not your input
distribution to the model. That's not the right thing.

DARMAN: I guess I'll leave it there. Thanks.

CODELL: It's hard.

MORTON: If I could -- I think I might be able to contribute
a little to that. What you want is a KD that would produce the

ADN
RIL
EY
&
ASS
OCI
ATE

1 concentration in the well that you would actually get on your site, one
2 KD that would produce that, because that one KD value is the only thing
3 you can use in your model. That's what he was talking about about the
4 effective KD; that is to say, a KD that -- one KD value that represents
5 the spatial variability on the site. How you get that from your
6 distribution of empirically determined KDs is magical.

7 CODELL: It can be done; it's just -- if you have the
8 resources to go out and collect lots of data and also run two and three
9 dimensional time dependent models that are very sophisticated, you can
10 do all this, but I'm saying I've never seen that kind of analysis
11 applied to these kinds of sites. They're not even applied to Yucca
12 Mountain in general.

13 EID: I think you could do a combination of deterministic
14 and probabilistic. If you have some site data, you could establish a
15 distribution which could be much, much narrower if you do not have site
16 data, so this distribution will be more realistic than the other
17 distribution that you use. So, I would say the site-specific data will
18 be useful to establish a narrower distribution.

19 ROBERTS: Rick Roberts.

20 It looks like this mean of peak doses methodology is fairly
21 well-known and entrenched in groundwater modeling. I guess my question
22 would be towards other pathways: soil ingestion, soil inhalation,
23 surface water ingestion, things like that. Is the NRC advocating that
24 this mean of peak doses methodology be applied to other pathways as
25 well?

EID: I would like to say that for metabolic and behavior
parameters, we adopted more or less the mean values for those, so I
think that the licensee could use the mean values, and those are
indicated in volumes one and two and three of NUREG 5512, so they would
be more or less consistent with the NUREG 5512 volumes one, two and

ADN
RIL
EY
&
ASS
OCI
ATE

1 three for the behavior and metabolic parameters.

2 For other parameters that are more site-specific or maybe
3 some of them, like soil indicium, for example, in developing the RESRAD
4 code, for example, there will be distributions for those.

5 THAGGARD: The answer to your question, I think what you are
6 saying is that curve he showed, the dose curve, would be a total dose
7 curve, so each time you run the -- each time you run the Monte Carlo
8 analysis, you're calculating a total dose, so you're getting a dose not
9 only from the groundwater pathway, but it would be the dose that you get
10 from the other pathways, too.

11 So, the example Dick gave, I think he just isolated on
12 looking at just a single pathway just to make the analysis simple, but
13 in reality, we're looking at the total dose.

14 EID: So, in other words, he will input other parameters,
15 too, besides these hydrologic parameters. Yes, there will be other
16 variable parameters, too, like, for example, the density of the
17 contaminated zone; the density of the unsaturated zone; the porosity
18 could be the soil indicia; other factors that, you know, the suspension
19 for the mass loading factors. So, those also, they would have
20 distributions.

21 ROBERTS: Okay; and I may be wrong, but it sounds like
22 you're using different methodologies for soil ingestion, inhalation and
23 other pathways than for groundwater ingestion, or are the methodologies
24 the same?

25 EID: No, those are input parameters to the code, and when
you run the probabilistic code, you will have these distributions for
those parameters, and when you try to make the runs, you calculate the
dose with these variables. So, you are varying also those input
parameters of the code. You are not just only varying hydrologic
parameters. There will be a distribution established for other

ADN
RIL
EY
&
ASS
OCI
ATE

1 parameters as well.

2 ROBERTS: And I think what you're talking about, I think, is
3 the left hand side of that analysis right there, looking at parameter
4 inputs, and I think the mean of the peak doses is actually -- and maybe
5 I have it wrong -- is actually keying on the Y variable on the right.
6 And so, I guess I'm still -- since I believe you're looking at the
7 left-hand side of that figure, I guess I'm looking more towards the
8 right hand side, where we're looking at the doses as the end product,
9 and how does the mean of peak doses, I guess, apply for other pathways
10 with respect to this type of methodology?

11 CODELL: It's really straightforward. It's not as
12 complicated as you might think. Your total dose is the sum of your
13 groundwater dose, your ingestion, the airborne inhalation dose. These
14 are all calculated with the codes like RESRAD as a function of time, and
15 so, you're adding up all of these doses, and you're really interested in
16 the total of all the pathways. So the same would apply for whether
17 you're talking about just groundwater or for all the pathways.

18 THAGGARD: Well, I think the easiest example would be to
19 take the RESRAD code, for example. You could run the RESRAD code and do
20 this problem in that each time you run RESRAD, you could sample the
21 parameters, and every time you sample the parameters, you get a dose
22 distribution curve. Now, that's a total dose curve, because it's
23 looking at all the pathways, and if each time you get a dose
24 distribution curve, you could take the peak from that curve, and so, if
25 you're running that 100 or 1,000 times, you're going to wind up with
1,000 results. And all we're saying is you take the mean of those
results.

ADN
RIL
EY
&
ASS
OCI
ATE

So, the dose that we're talking about is the total dose.
It's the dose from all of the pathways. Maybe you got a little bit
confused because Dick isolated on just the groundwater pathway in his

1 example, but that example could have been -- it could have looked at all
2 of the pathways. I mean, he could have done that example using RESRAD,
3 for example, where you get a total dose.

4 ROBERTS: Okay; so, this does apply to all pathways. Now,
5 is there going to be something that explains how this is applied to all
6 pathways later on, how that's actually going to be performed, some type
7 of guidance?

8 EID: Yes; we will try to explain that when we talk about
9 the models and codes, and we'll try to put something in this regard to
10 explain it.

11 ROBERTS: Okay; thank you.

12 MORTON: A couple of questions to help clarify that.

13 If I think of RESRAD or D&D as being a collection of
14 deterministic models, and if I select or make the selection that it run
15 models of several pathways; that is, if I think of a model for each
16 pathway, and I select several pathways, I put in one set of values of
17 input parameters, and that collection of models calculates the dose from
18 each pathway, adds it, and gives me the result as a function of time and
19 can pick out --

20 EID: That is correct.

21 MORTON: -- the max.

22 EID: Yes.

23 THAGGARD: Correct.

24 MORTON: So, in way of explanation, would we then say is the
25 -- is the conversion of this collection of models in this code set from
a deterministic collection to a probabilistic collection done by
grafting on or integrating onto the front end a probability selection
module for each of the input parameters that you're interested in
& varying?

CODELL: Precisely.

ADD
RIL
EY
&
ASS
OCI
ATE

1 MORTON: So, in effect, then, what one has is the ability to
2 set up RESRAD or D&D as you ordinarily would in a deterministic model
3 but, in addition to that, enter the range and probability type for those
4 variables that you want to vary.

5 EID: That is correct.

6 MORTON: That you want to sample probabilistic.
7 For sensitive parameters, that is correct. And when you do that, then,
8 they'll take a sample from each of those; feed that individual value of
9 that sample parameter into the model for each of the pathways you've
10 selected; and run it as a deterministic model.

11 CODELL: That's right.

12 MORTON: So maybe that helps explain it.

13 EID: Yes.

14 MORTON: My question otherwise would be is RESRAD and -- are
15 RESRAD and D&D both going to be designed in fundamentally that way? Are
16 the probabilistic version of RESRAD and the probabilistic version of D&D
17 going to be similar in structure?

18 THAGGARD: In terms of how similar the codes are, I don't
19 know about that, but yes, both of the codes are going to be capable of
20 doing exactly what you said. Actually --

21 MORTON: Yes; I'm not asking about the models of the
22 individual pathways. I know there are differences in those, but just in
23 the structure of how you would conceive of the probabilistic version
24 working for each of these two.

25 EID: We are actually currently doing that, and we have
jointly in our -- Sandia, our contractor and ANL, they are getting
together, and we are discussing this issue and to see how each modeling
code will deal with this uncertainty. I cannot guarantee that they are
exactly the same, but we are trying to look, and we are now currently
testing the beta version of D&D, version two, and also possibly, for the

ADN
RIL
EY
&
ASS
OCI
ATE

1 next month or so, will be testing a beta version of RESRAD
2 probabilistic, and then, we are looking into that.

3 MORTON: There was that linkage problem between
4 radionuclides in the early version of D&D. Is that going to be resolved
5 in these two versions, that is, the later version of D&D and the version
6 of RESRAD?

7 EID: Can you say what is that problem in D&D? Can you say
8 that?

9 MORTON: Yes; that's when you had multiple radionuclides --

10 EID: Oh, okay.

11 MORTON: -- it compounded the upper end --

12 EID: Right.

13 MORTON: -- it compounded the probability.

14 EID: Yes; this issue, for sure, is that's one of the major
15 reasons for developing version two. This is going to be resolved as,
16 you'll remember, we talked about anomalies in the dose values for
17 version one, and that's one of the major reasons we went further for
18 developing version two. So, it will be resolved.

19 CULBERSON: Dave Culberson.

20 At the risk of showing my ignorance here, I'm not a
21 statistician, and I'm not highly technical, but I wanted to make sure I
22 understand something. Did I understand you correctly that a licensee
23 could elect, using KD as a value, as an example, a licensee could elect
24 to take multiple samples across the site, come up with a mean number for
25 the KD and use that in the models as opposed to using the most
conservative of that distribution? Is that --

CODELL: Well, close but not quite. You see, the problem is
-- I wish I could draw this somehow -- the problem is that you can take
values of a parameter on a site -- suppose you just created a square
grid, and everywhere on the grid, you go out, and you collect a soil

ADDN
RIL
EY
&
ASS
OCI
ATE

1 sample, and you take it, and you analyze its KD or whatever the
2 parameter is. Maybe I don't need to write -- but you could then -- you
3 then would have a list of data. Let me draw this; okay. So, you have
4 your site here, and you do some sort of an organized sampling procedure,
5 and you go and collect data from all of these points here, and you have
6 a long list of data, of KD.

7 Now, what you have here is a long list of data, and you can
8 do lots of things with it. You can take its average, and then, you
9 could say I know the average; I know the standard deviation; I know
10 other things about this distribution. I could draw this -- I could make
11 a histogram of this distribution like this, so this is KD, and you have
12 a density function that looks like the distribution. You can do all
13 those things with it.

14 But taking the mean value and plugging it into the model is
15 not necessarily correct. It might be, but you don't know. What if all
16 of your high values were over here, okay, and all your low values were
17 over here? Would it make sense to take the mean? Well, I don't know.
18 Probably not. What you really have to do is find out what is the single
19 value of KD that you'd plug into your model that would give you the
20 correct result, and that's easier said than done, because you would have
21 to do the very hard model in the first place. You would have to do a
22 two-or-three-dimensional model to find that out. That's the rub.

23 CULBERSON: So, in that case, what is the licensee's
24 alternative?

25 CODELL: Well, I don't have the answers to very hard
problems like that. I wish I did.

EID: I think currently, what we will do, we will look to
the dose values using the mean of the KD values and look at the bounding
analysis if you have the higher and the lower side, and we see what kind
of variations we have. That's the staff is going to assist the

ADN
RIL
EY
&
ASS
OCI
ATE

1 deterministic approach, although we prefer to have, of course, more
2 conservative values than the mean, but we'll look into the dose values,
3 and we may run probabilistic analysis to assist how far we are from the
4 conservative dose.

5 THAGGARD: Well, let me correct Bobby on something.
6 Actually, this whole issue is something that we're still working on. I
7 mean, this part of the technical basis document, we have not finished
8 yet, and so, this may be one of these type of issues that, you know, you
9 may have to wait until we get the document out there on the Website to
10 get a full answer to the question.

11 CULBERSON: Well, from a more practical standpoint, if we
12 have a licensee who is ready to come in with a plan today or tomorrow,
13 what would they use? I mean, do they go to reference books? Do they
14 use a single sample? Do they use a worst-case KD on their site out of a
15 sampling of 10 samples? What, practically speaking --

16 CODELL: You'd start off doing the most conservative thing
17 you could do and see whether it's acceptable, and then, if it isn't,
18 then, you could refine your analyses. That's what we're talking about
19 iterative performance assessments.

20 POTTER: Tom Potter.

21 This is where you have to get creative on your site again.
22 For example, if all of those high values were real high, and you could
23 calculate from that that material up in that range is not going to leave
24 the contaminated zone, you could confine your analysis to the part of
25 that zone where the KDs are low and do an analysis on that basis or
something like that. A conservative approach would be use KDs from the
lower end to apply to the whole site. There are a variety of ways to
kind of narrow in on it.

CODELL: Right; if this is your distribution of the results
and low KDs, you might pick something on the low side, so you -- to

ANN
RIL
EY
&
ASS
OCI
ATE

1 start with, and this is, I guess, what -- if you're an experienced
2 analyst, you would start off doing the least you had to, the cheapest
3 thing, first, rather than spending your employer's money on more
4 sophisticated analyses.

5 Did I see another question there?

6 PRICE: It's Joe Price with SAIC again.

7 In 1998 or so, there were two letter reports that
8 accompanied draft reports of NUREG 1549. The lead author's name was
9 Beiler. One was for the residential agriculture, and one was for the
10 building reuse scenarios. They gave surrogate probability distributions
11 for a lot of important parameters. Do you think, if you were going to
12 use surrogate information in a site-specific analysis, would those
13 distributions be what NRC thinks is appropriate, or has that changed?

14 THAGGARD: Those are the distributions that are going to be
15 in D&D version two, and certainly, the intent is if you didn't change
16 anything in that code, that's what you're actually running. Now, if
17 you're going to do a site-specific analysis, ideally, you would probably
18 want to narrow those distribution ranges with the assumption that you
19 know more about the site -- I mean, know more about the parameter, and
20 so, you've got some justification for narrowing it, but that certainly
21 would be one way -- I mean, one place to start, just look at those
22 distributions. But they're based on national data, so, presumably, at
23 your particular site, distribution should be a lot smaller.

24 CODELL: In fact, you could use -- you can use the
25 inferences from the regional or national data and a few site-specific
data to come up with a more appropriate distribution that you could use
on your site.

ADN
RIL
EY
&
ASS
OCI
ATE
THAGGARD: Yes; that's where we get into this thing about
the Bayesian updating approach and things of that nature.

EID: Also, in developing RESRAD probabilistic, we will have

1 also a distribution of parameters that you could use when the code is
2 ready.

3 PRICE: That will be different from what's in those support
4 documents, or will they be the same?

5 EID: Some of them, they are consistent; others, more
6 updated. There are certain parameters that are more updated, actually,
7 than those letter reports.

8 CODELL: Are you talking about the ones for --

9 EID: RESRAD.

10 CODELL: The ANL?

11 EID: Yes, the ANL contract.

12 CODELL: Right.

13 EID: Also, we have the contract with PNL about hydrologic
14 parameter distribution. That's another source of information that you
15 could use. And we mention that in the SRP, we refer to it.

16 PRICE: Is that information publicly available now, or will
17 it be in the future?

18 EID: It is a contract which is about to be completed, and
19 then, it will be, you know, used as -- either as reference to a NUREG,
20 be a reference to it, or some information may be included in the SRB
21 technical basis documents.

22 THAGGARD: Well, the NUREG, actually, is down at the
23 publisher's now, so it should be published any week now.

24 POTTER: Do you have the number on that?

25 THAGGARD: No, unfortunately, I don't.

EID: We'll provide it to you later if you'll give me your
card.

DARMAN: On the new version of D&D, going back to this view
& chart here --

CODELL: Which one is that?

ANN
RIL
EY
&
ASS
OCI
ATE

1 DARMAN: Where you had the mean of the peaks and the peak of
2 the means.

3 CODELL: Oh, yes, okay.

4 DARMAN: Which one is that version going to output?

5 THAGGARD: Well, whichever approach we settle on, that's
6 what it's going to have.

7 DARMAN: Okay. It's not going to have -- it hasn't been
8 decided yet?

9 THAGGARD: No, right now, we've got a -- just a beta version
10 of the codes, and the contractor is -- that's one of the inputs that
11 we've still got to get a contractor.

12 CODELL: Anyone else?

13 [No response.]

14 CODELL: Take your best shot.

15 [Pause.]

16 ORLANDO: Okay; if that's it, well, thank you, Mark and
17 Bobby and Dick. Does anybody have any more questions on anything?

18 [No response.]

19 ORLANDO: The good news is I think it's raining outside,
20 which means it's probably melting all of the stuff that was holding up
21 any airplanes.

22 Does somebody have a question in the audience?

23 SPEAKER: Will we hear from Bobby? It sounds like you're
24 wrapping it up.

25 EID: Well, I think, you know, what we are doing now, still,
we are in progress for developing the SRP dose modeling. The technical
basis documents, I believe, will be the most important parts of the SRP,
because, of course, I am not underestimating the importance of the
others, but those, they will be the areas where many licensees, they are
not familiar with, and hopefully, we will try to put those together.

ADN
RIL
EY
&
ASS
OCI
ATE

1 Also, we will put those on the Website, hopefully, in April.

2 Please try to keep your eyes open to read those. They will
3 impact the way you do dose modeling analysis, and they are very
4 important. Please read those when they are on the Web and try to give
5 us your feedback, and we are not, you know, coming to the end right now.
6 We are developing the codes; we are developing the models, assisting the
7 beta versions of both RESRAD and D&D, and we will try to make changes,
8 but we would like to have your feedback, so please, you know, let us
9 know and communicate with us whether through the Internet or through
10 phone calls or even in writing.

11 We are trying to finalize now, hopefully by June when we
12 have the next workshop, we will have similar workshops like this. It
13 will be a very lively workshop hopefully regarding dose modeling, and
14 then, we will try to make the changes, and hopefully by that time, we
15 will be developing the final SRP in July.

16 Again, the SRP, although we call it is final in July, it
17 will be a dynamic document that we could change it also, and we will
18 come and make the changes. The codes and models hopefully will be
19 available in the summertime, so by the time the SRP is coming out in
20 July, so hopefully, also, we will have the models and codes,
21 probabilistic models and codes will be available for public use.

22 THAGGARD: I think there was probably some confusion. I
23 think Nick told everybody that Bobby was going to give a presentation,
24 and the confusion was that actually, Dick was giving the presentation.

25 ORLANDO: I apologize for that. I thought that Bobby had
said that before we got into the presentation.

EID: I want to thank you all again for your feedback, and,
you know, hopefully, we will get more information in the future.

ORLANDO: Dave, did you have something you wanted to add?

CULBERSON: Yes. This is Dave Culberson.

ADDN
RIL
EY
&
ASS
OCI
ATE

1 Just a final comment. I just want to express appreciation.
2 I think this was a good workshop. All of them have been helpful. We
3 appreciate NRC involving licensees in these discussions. I think there
4 has been a real healthy exchange of information, a lot of information
5 passed back and forth, which is always good for understanding on both
6 sides, and I would encourage continued participation. We are more than
7 willing to do what we can as the Fuel Cycles Facility Forum, and I just
8 applaud your effort to try to make this process clear and painless and
9 helpful to everybody.

10 ORLANDO: That's our goal, too.

11 Now, if anybody has any other questions or comments, does
12 anybody have anything to say about any SRP modules?

13 [No response.]

14 ORLANDO: Okay; well, then, thank you very much. Everybody
15 be careful going home, and I hope you all make it.

16 [Whereupon, at 11:05 a.m., the workshop was concluded.]
17
18
19
20
21
22
23
24
25

ADN
RIL
EY
&
ASS
OCI
ATE